Login    Join free Add to favorites    中文
home > news > Merck Completes Third and Final Registration Phase
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
Merck Completes Third and Final Registration Phase

hits:323     Date:06/07/18
Merck Completes Third and Final Registration Phase under the European Chemicals Regulation REACH
 
Merck today announced that it has successfully submitted a total of more than 1,000 registration dossiers under the European chemicals regulation REACH ...
 
  • More than 1,000 registration dossiers successfully submitted for safe use
 
Darmstadt, Germany, June 6, 2018 鈥 Merck, a leading science and technology company, today announced that it has successfully submitted a total of more than 1,000 registration dossiers under the European chemicals regulation REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) by the end of the third and final registration deadline of May 31, 2018. This process also includes substances from Sigma-Aldrich, which were added to the existing portfolio of Merck as a result of the largest acquisition in the company鈥檚 350-year history.
 
鈥淭hrough the successful completion of the requested registrations, Merck presents itself as a reliable and competent partner to its customers and products sold by Merck comply with current requirements under REACH,鈥 said Robert Nass, Senior Vice President, Quality and Regulatory Management at the Life Science business sector, and Andreas Kruse, Executive Vice President, Integrated Supply Chain at the Performance Materials business sector.
 
The registrations aim to ensure the safe use of chemicals in the marketplace. The basis for this is an extensive substance dossier. This dossier contains data on physico-chemical, toxicological and ecotoxicological properties, as well as on the use of a substance.
 
Even though the final registration deadline for REACH has been successfully met, REACH activities are not completed with the end of this transition period. New substances must be continuously registered and already existing registration dossiers constantly updated, or expanded by new data in the course of evaluations. This continues to ensure safe use of the substances as well as sustainable and responsible marketability of the products.
 
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 53,000 employees work to further develop technologies that improve and enhance life 鈥 from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2017, Merck generated sales of 鈧 15.3 billion in 66 countries.
 
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Related News>> more
advertisement

Copyright(C) 2006-2018 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙